NCT04156828View on ClinicalTrials.gov

Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 31, 2020

Primary Completion Date

April 27, 2022

Study Completion Date

June 8, 2023

Conditions
Grade 3b Follicular LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular LymphomaRefractory Diffuse Large B-Cell LymphomaNon-Hodgkin's Lymphoma
Interventions
DRUG

Copanlisib

Given IV

DRUG

Gemcitabine

Given IV

DRUG

Carboplatin

Given IV

DRUG

Dexamethasone

Given PO

BIOLOGICAL

Rituximab

Given IV

BIOLOGICAL

Pegfilgrastim

Given SC

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

University of Washington

OTHER

NCT04156828 - Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma | Biotech Hunter | Biotech Hunter